RE:New posterHey Retiresoon. Welcome. I'd say there are several near term bullish catalysts and only one downside catalyst. Downside is FDA refusing our BLA submission or new trial needed. Potential upside catalysts are: Orphan drug approval, Journal article, MCNA partnership with up front funds, hostile bid, EU submission (have never heard anything about that -just surmising) FDA Special protocol, name change, US listing, runup to BLA submission, runup to FDA decision. All of these have the potential to take us higher, but none compare to what an FDA approval will do for the stock. I think we may trade over $1.50 prior to FDA decision. Approval should propel us over $3 and attaching a growth multiple once sales get rolling, could get us over $5 to $7 per share. So I'd say buy a lot more and you willlikelyretiresoon. I'd buy more, but my broker (me) advised me to stop at 70% of my portfolio:>) GL beech